We work with specialist partners in local markets through licensing or distribution agreements. Our existing partnerships are listed below. We would be interested in partnering, out-licensing and in-licensing other opportunities within the neurology field. If you would like further information regarding potential partnership opportunities, please contact us.

Putting Patients First

We seek to develop products that represent advancements by offering enhanced modes of delivery, more convenient treatment regimens, improved resistance profiles, reduced side effects and greater efficacy. Through our own research and partnerships with universities, medical research institutions and global pharmaceutical leaders, Volks laboratory Inc is rapidly and efficiently making scientific and clinical advancements that raise the standard for new therapeutics that treat life-threatening diseases.

• Atripla®

  efavirenz 600 mg/emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg

• Biktarvy®

  bictegravir 50 mg/emtricitabine 200 mg/tenofovir alafenamide 25 mg

• Complera®

  emtricitabine 200 mg/rilpivirine 25 mg/tenofovir disoproxil fumarate 300 mg

• Descovy®

  emtricitabine 200 mg/ tenofovir alafenamide 25 mg

• Emtriva®

  Emtriva® emtricitabine 200 mg

• Genvoya®

  elvitegravir 150 mg/cobicistat 150 mg/ emtricitabine 200 mg/tenofovir alafenamide 10 mg

Our main objective is to improve the quality of life of the People with Parkinsons disease. We are committed to investment in device developments to provide innovative, high quality results to address unmet needs of patients with Parkinson’s disease.

We understand that life-changing therapies aren’t enough and often patients require assistance with their general wellbeing and in collaboration with our Global Partner Network we support patients & carers throughout their Parkinson journey.